Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,124.00
Ask: 12,128.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: Barratt Profit Up; Interserve Gets Debt Deal

Wed, 06th Feb 2019 07:46

LONDON (Alliance News) - Stock prices in London on Wednesday are set to pull back from Tuesday's rally, while the pound remained below the USD1.30 mark after disappointing UK data released earlier in the week.In early company news, Barratt Developments said interim profit jumped amid higher revenue and stronger margins, while Victrex warned of a weaker first quarter, and Interserve reached a deal to cut debt via issuing just under GBP500 million in fresh equity. Due at midday are annual results form GlaxoSmithKline.IG says futures indicate the FTSE 100 index of large-caps to open 11.27 points lower at 7,166.10 on Wednesday. The FTSE 100 index closed up 2.0%, or 143.24 points, at 7,177.37 on Tuesday.After Tuesday's "bumper" move higher, stocks in London are set to pull back slightly on Wednesday, said CMC Markets chief market analyst Michael Hewson."Investors piled back into equity markets, sending the FTSE 100 to three-month highs, and European stocks to their highest levels in two months. The rise in the FTSE was helped by a weaker pound as well as a well-received set of numbers from oil giant BP," explained Hewson. Sterling had slumped on Tuesday after the latest UK services Purchasing Managers' Index came in at 50.1 in January, down from 51.2 in December and only marginally above the stagnation mark of 50. The pound was quoted at USD1.2929 early Wednesday, soft compared to USD1.2936 at the London equities close on Tuesday and remaining substantially below USD1.3059 as at the equities close on Monday.The services data on Tuesday followed news on Monday that UK construction growth eased further in January to its weakest level in ten months, while on Friday last week figures showed the country's manufacturing sector made a lacklustre start to 2019, slipping to its lowest level in three months.In company news, housebuilder Barratt Developments reported a double-digit rise in half-year profit.Revenue for the six months to December 31 rose 7.2% to GBP2.13 billion from GBP1.99 billion a year ago, as completions rose 4.1% to 7,622. Pretax profit jumped 19% year-on-year to GBP408.0 million as the company's gross margin improved by 200 basis points to 22.6%.The home builder raised its interim dividend by 12% to 9.6p. The FTSE 100 constituent said trading is in line with expectations and it is "confident" in achieving a "good financial and operational performance" in its current financial year. Barratt said it intends to pay a special return of GBP175 million in November 2019, as previously announced, and to demonstrate management's confidence it has proposed to pay a further GBP175 million in November 2020.Smaller peer Redrow said revenue in the half-year to December 31 grew 9% to GBP970 million as pretax profit increased 5% to GBP185 million. Legal completions rose 12% to 2,970The firm boosted its interim dividend by 11% to 10p. In addition to this, Redrow proposed a 30p per share return to shareholders through a 'B' share scheme. "The market during the run up to the festive period and the first two weeks of 2019 was subdued by macroeconomic and political uncertainty. However, sales over the last three weeks have bounced-back with reservations running at similar levels to last year's strong market activity," said Redrow's outgoing chair, Steve Morgan.Drugmaker AstraZeneca said the US Food & Drug Administration has granted Orphan Drug Designation to Fasenra for the treatment of hypereosinophilic syndrome. The FDA grants this designation to treatments of rare diseases or disorders that affect fewer than 200,000 people in the US.Water firm Severn Trent said it continues to expect a full-year trading performance in line with expectations. The blue-chip firm said its capital programme is progressing well and it is on track to deliver its "biggest capital spend in a decade. Victrex said it had a weaker start to its financial year, though has seen a pick-up in recent months. The high performance polymer firm said first quarter revenue was down 18% on last year at GBP64.1 million, with sales volumes of 822 tonnes down 22% year-on-year. "Pleasingly, January and February saw some initial improvement, although given our Q1 performance, the first half is expected to be much weaker overall, compared to the prior year. Our expectations for the second half are unchanged, with new projects and reduced headwinds supporting our assumptions," said Chief Executive Jakob Sigurdsson.Struggling support services firm Interserve said it has reached an agreement to cut debt via issuing new equity, and separately said it has received a letter from a shareholder requesting the removal of the majority of the board.Interserve said it has agreed a deleveraging plan in principle with its lender, bonding provider and the pension trustee, which is expected to result in the firm's net debt being reduced to GBP275 million. This will be done through the issue of GBP480 million in fresh Interserve equity. Interserve currently has a market capitalisation of GBP149.7 million, meaning existing shareholders face significant dilution.The new Interserve equity will be provisionally placed with existing lenders and subject to "claw back in full" by existing shareholders through a fully pre-emptive open offer."Whilst Interserve's objective remains to implement a fully consensual transaction, Interserve is also actively preparing alternative plans to ensure the proposed transaction can be implemented in the event that shareholder approval is not forthcoming," the company noted.Separately, Coltrane Master Fund has requisitioned a general meeting of Interserve, in which it has proposed the removal of Glyn Barker, Mark Whiteling, Russell King, Anne Fahy, Nick Salmon, Gareth Edwards, Dougie Sutherland and Nicholas Pollard as directors of Interserve. Coltrane does, however, continue to support Chief Executive Debbie White and is not seeking her removal. White is the only member of the Interserve board that Coltrane is not looking to remove.Atlas Mara said it is undertaking a strategic review and also announced Bob Diamond will step down as chair and return to his previous role of non-executive director.The African bank investor said it will be looking to reduce exposure in non-core markets, accelerate an agricultural finance platform, achieve the consolidation of the Union Bank of Nigeria, and develop a digital banking platform.In addition, Atlas Mara founder Diamond has decided to move from his role as chair and return to being a non-executive director on the board. Diamond assumed the role of chair on an interim basis, the company explained. Atlas Mara has appointed Michael Wilkerson, a non-executive director, to assume the role of executive chair.Still to come in Wednesday's UK corporate calendar are annual results from pharmaceuticals giant GlaxoSmithKline.In the US on Tuesday, Wall Street ended higher, with the Dow Jones Industrial Average closing up 0.7%, the S&P 500 up 0.5% and Nasdaq Composite gaining 0.7%.After the New York close, entertainment giant Walt Disney reported a fall in profit as revenue edged marginally lower. California-based Disney's first-quarter profit dropped to USD2.79 billion or USD1.86 per share from USD4.42 billion or USD2.91 per share a year before. The previous year's bottom line included a USD1.6 billion one-time tax benefit associated with US federal tax reforms. Revenue for the quarter was relatively flat at USD15.30 billion compared to USD15.35 billion a year before. Focus on Tuesday evening in the US was on US President Donald Trump's State of the Union address, though investors looking for a "fresh trading catalyst" were left disappointed, said Jasper Lawler, head of research at London Capital Group."The US dollar remained steady following President Trump's address. Whilst the President touched on Chinese trade relations and the budget there was nothing new for traders to sink their teeth into," said Lawler. Urging unity and cooperation across party lines, Trump on Tuesday hailed the country's economy while honing in on his signature issues of illegal immigration and a wall on the border with Mexico during his State of the Union address.In a response to Trump's speech, House Speaker Nancy Pelosi accused the president of "fear-mongering and manufacturing a crisis at the border".Trump's insistence on the wall led to a partial government shutdown in December and January, and funding again runs out on February 15, with no deal in sight.In Asia on Wednesday, the Japanese Nikkei 225 index closed closed up 0.1%. Financial markets in China and Hong Kong were closed for the Lunar New Year holiday. Trump said he would meet North Korean leader Kim Jong Un in Vietnam on February 27-28 for their second summit. "As part of a bold new diplomacy, we continue our historic push for peace on the Korean Peninsula," he told Congress in his State of the Union address.In the economic calendar on Wednesday are German factory orders at 0700 GMT followed by the US trade balance at 1330 GMT.

More News
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.